Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, April 16, 2021
[ Fri, Apr 16th 2021
] - WOPRAI
[ Fri, Apr 16th 2021
] - WOPRAI
[ Fri, Apr 16th 2021
] - WOPRAI
[ Fri, Apr 16th 2021
] - WOPRAI
[ Fri, Apr 16th 2021
] - WOPRAI
[ Fri, Apr 16th 2021
] - WOPRAI
[ Fri, Apr 16th 2021
] - WOPRAI
[ Fri, Apr 16th 2021
] - WOPRAI
[ Fri, Apr 16th 2021
] - WOPRAI
[ Fri, Apr 16th 2021
] - WOPRAI
[ Fri, Apr 16th 2021
] - WOPRAI
[ Fri, Apr 16th 2021
] - WOPRAI
[ Fri, Apr 16th 2021
] - WOPRAI
[ Fri, Apr 16th 2021
] - WOPRAI
[ Fri, Apr 16th 2021
] - WOPRAI
[ Fri, Apr 16th 2021
] - WOPRAI
[ Fri, Apr 16th 2021
] - WOPRAI
[ Fri, Apr 16th 2021
] - WOPRAI
[ Fri, Apr 16th 2021
] - WOPRAI
[ Fri, Apr 16th 2021
] - WOPRAI
[ Fri, Apr 16th 2021
] - WOPRAI
[ Fri, Apr 16th 2021
] - WOPRAI
[ Fri, Apr 16th 2021
] - WOPRAI
[ Fri, Apr 16th 2021
] - WOPRAI
[ Fri, Apr 16th 2021
] - WOPRAI
[ Fri, Apr 16th 2021
] - WOPRAI
[ Fri, Apr 16th 2021
] - WOPRAI
[ Fri, Apr 16th 2021
] - WOPRAI
Madhu Kumar Initiated (APLS) at Strong Buy and Held Target at $130 on, Apr 16th, 2021
Madhu Kumar of Goldman Sachs, Initiated "Apellis Pharmaceuticals, Inc." (APLS) at Strong Buy and Held Target at $130 on, Apr 16th, 2021.
Madhu has made no other calls on APLS in the last 4 months.
There are 2 other peers that have a rating on APLS. Out of the 2 peers that are also analyzing APLS, 1 agrees with Madhu's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Tiago Fauth of "Credit Suisse" Maintained at Hold with Increased Target to $37 on, Friday, February 26th, 2021
This is the rating of the analyst that currently disagrees with Madhu
- Steven Seedhouse of "Raymond James" Maintained at Strong Buy with Increased Target to $104 on, Friday, January 8th, 2021
